- STAT+: Next-gen Duchenne drug from Entrada disappointsA next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.STAT · 2mo ago↗ source
- STAT+: Color me skeptical: Drinking gold is not an ALS cureIn this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.STAT · 2mo ago↗ source
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1BThe Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.STAT · 2mo ago↗ source